Statement 2
Accepting that nonadherence may be both intentional and unintentional, do you agree that between 30% and 50% of severe asthma patients in the most severe and difficult asthma clinics are poorly adherent with inhaled corticosteroid treatment as the primary clinical problem?
Consensus achieved
Physician view Group 1 felt this proportion was 30-50%, group 2 thought 25-50% and group 3 thought 20-50%.
Patient view
94% of patients reported they would never miss taking their inhalers.
Statement 3a
Do you agree that at least 5 mg (or 2.5 mg if on ⩽10 mg·day −1 ) reduction in daily oral prednisolone would be regarded as a clinically meaningful reduction?
Consensus achieved
Uncertainty as to clinicians' opinions of using a biomarker-based management approach to corticosteroid adjustment versus symptoms, lung function and exacerbation history What level of steroid reduction is required to define using a biomarker-based algorithm as clinically worthwhile? 
Statement 3b
If you treat patients with asthma on maintenance oral steroids, do you agree that at least 25% of patients would be required to be on this optimised "lower" dose of daily oral prednisolone treatment to justify routine use of biomarker-based corticosteroid treatment adjustment in routine clinical care?
Consensus achieved
Physician view All expert physician groups agreed that at least 5 mg (or 2.5 mg if ⩽10 mg·day
) reduction in prednisolone was clinically meaningful. Group 1 thought that at least 25% of patients would need to make this reduction to justify a biomarker-based strategy, whilst groups 2 and 3 thought at least 20%.
Patient view 91% of patients felt any reduction in oral corticosteroids would make blood/breath tests worthwhile.
Statement 4a
Do you agree that in a severe asthma population on high-dose inhaled steroids (2000 µg beclomethasone dipropionate equivalent dose) that at least a 500 µg reduction in daily inhaled corticosteroid treatment would be regarded as a clinically meaningful dose reduction?
Consensus not achieved
Statement 4b
Do you agree that at least 30% of patients would be required to be on this optimised "lower" dose of daily inhaled corticosteroid treatment to justify routine use of biomarker-based corticosteroid treatment adjustment in routine clinical care?
Consensus not achieved
Physician view Group 1 agreed that at least 500 µg reduction was clinically meaningful and group 2 thought this was at least 250 µg reduction. For group 3, 62% felt that at least 250 µg reduction was clinically meaningful (no consensus). Groups 1 and 2 agreed that at least 30% of patients would need to be on this optimised lower dose to justify using a biomarker-based adjustment strategy; for group 3, 54% felt that at least 40% of patients would need to achieve this (no consensus).
Patient view 73% of patients felt that additional blood/breath tests would be worthwhile if they led to any reduction in inhaled corticosteroid treatment.
Statement 5
Accepting at least three exacerbations per year (requiring oral corticosteroid rescue therapy), do you agree that at least a 30% reduction per year would be an acceptable reduction to justify routine use of biomarker-based corticosteroid treatment adjustment?
Consensus achieved
Physician view Group 1 agreed that at least a 30% reduction in asthma exacerbations per year would justify routine use of biomarker-based corticosteroid treatment adjustment whereas groups 2 and 3 agreed that at least a 20% reduction would justify routine use.
Patient view 44% of patients had three or more asthma attacks in the previous year requiring oral corticosteroids. All patients thought that having regular blood and breath tests would be worthwhile if this prevented one attack.
Statement 6
Excluding patients where persistent symptoms of cough, wheeze and breathlessness are due to comorbid conditions (e.g. obesity, vocal cord dysfunction, dysfunctional breathing, rhinosinusitis, etc.), do you agree that at least 25% of remaining severe asthma patients in your clinic have persistent symptoms due to asthma that are not corticosteroid responsive?
Consensus achieved
Physician view Groups 1 and 2 agreed at least 25% and group 3 agreed at least 20% of severe asthma patients have persistent symptoms due to asthma that are not corticosteroid responsive.
Patient view 91% of patients agreed that not all their symptoms responded to inhaled or oral steroids.
The RASP-UK programme is exploring if a non-sputum biomarker-based adjustment of corticosteroid treatment is clinically more beneficial than standard care [7] . In this modified Delphi exercise, consensus was reached on all issues for groups 1 and 2. However, for group 3, consensus was not reached on a number of issues, including clinically meaningful dose reduction in inhaled corticosteroid treatment and proportion of patients reducing inhaled corticosteroid treatment to justify routine use of biomarkers. Overall, European experts appeared less supportive of biomarker-based corticosteroid adjustment compared to UK physicians and correctly stated that although sputum eosinophil count was evidence based, delivery was difficult in routine care and the optimal combination of non-sputum-based biomarkers was unknown [10, 11] .
Patient views are critical in understanding acceptance of treatment strategies and there was no consensus on corticosteroid treatment adjustment using symptoms versus biomarkers, suggesting education may be required on the utility of biomarkers in targeting treatment. The majority felt any reduction in inhaled/ oral corticosteroid dose or eradicating one severe exacerbation would make biomarker tests worthwhile. Patients felt regular blood and breath tests were unlikely to improve adherence; however, this small motivated group reported never missing medication. The group of patients who took part in this survey volunteered for Asthma UK and some were also involved in the Patient Input Platform for the RASP-UK programme. These patients may, therefore, have had greater knowledge regarding severe asthma and biomarkers.
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